NDUFAB1 and cardiomyopathy: Our findings substantiate that targeting mitochondria for greater bioenergetic capacity and repressed ROS emission with enhanced SC formation is an effective strategy for cardio-protection, and mark NDUFAB1 as a potential therapeutic target for the prevention and treatment of cardiomyopathy.